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Background: Therapeutic approaches using monoclonal anti-
bodies (mAbs) against complement regulatory proteins 
(CRPs:i.e.,CD46,CD55 and CD59) have been reported for 
adjuvant cancer therapy. In this study, we generated a re-
combinant 1E8 single-chain anti-CD59 antibody (scFv-Fc) 
and tested anti-cancer effect.by using complement depend-
ent cytotoxicity (CDC). Methods: We isolated mRNA from 
1E8 hybridoma cells and amplified the variable regions of the 
heavy chain (VH) and light chain (VL) genes using reverse- 
transcriptase polymerase chain reaction (RT-PCR). Using a 
linker, the amplified sequences for the heavy and light chains 
were each connected to the sequence for a single polypep-
tide chain that was designed to be expressed. The VL and 
VH fragments were cloned into the pOptiVEC-TOPO vector 
that contained the human CH2-CH3 fragment. Then, 293T 
cells were transfected with the 1E8 single-chain Fv-Fc 
(scFv-Fc) constructs. CD59 expression was evaluated in the 
prostate cancer cell lines using flow cytometry. The enhance-
ment of CDC effect by mouse 1E8 and 1E8 scFv-Fc were 
evaluated using a cytotoxicity assay. Results: The scFv-Fc 
constructs were expressed by the transfected 293T cells and 
secreted into the culture medium. The immunoreactivity of 
the secreted scFv-Fc construct was similar to that of the 
mouse 1E8 for CCRF-CEM cells. The molecular masses of 
1E8 scFv-Fc were about 120 kDa and 55 kDa under reducing 
and non-reducing conditions, respectively. The DNA se-
quence of 1E8 scFv-Fc was obtained and presented. CD59 
was highly expressed by the prostate cancer cell line. The re-
combinant 1E8 scFv-Fc mAb revealed significantly enhanced 
CDC effect similar with mouse 1E8 for prostate cancer cells. 
Conclusion: A 1E8 scFv-Fc construct for adjuvant cancer 
therapy was developed.
[Immune Network 2012;12(1):33-39]
INTRODUCTION
The complement system is an essential component of innate 
immunity and is involved in host defense against micro-or-
ganisms and other infectious agents (1,2). However, the acti-
vated  components  of  complement  produced  during  inflam-
mation  and  immune  responses  can  attack  the  host  cells  in 
the absence of a system of protection (3). Membrane-bound 
complement-regulatory  proteins  (CRPs),  including  CD55, 
CD59, and CD46, play roles in this process. As the CRPs are 
expressed  in  almost  all  human  tissues  and  are  able  to  in-
activate  complement  components,  under  normal  conditions 
there  is  no  bystander  effect  from  circulating  complement 
(4,5).
  A m o n g  t h e  C R P s ,  h u m a n  p r o t e c t i n  ( C D 5 9 )  i s  a n  1 8 ∼
25-kDa glycoprotein that is linked to the cell membrane via 
a  glycosylphosphatidylinositol  (GPI)  anchor.  CD59  inhibits 
complement-mediated  lysis  by  preventing  the  full  assembly 
of  the  membrane  attack  complex  (MAC)  on  host  cells.  It 
binds to C8 in the C5b-8 complex, preventing the polymer-
ization of C9 during the final step of MAC formation (6-10). 
Inhibition of CD59 function by an anti-CD59 mAb sensitizes 
tumor  cells  to  complement  attack  (11-15).  In  addition, 
CD59-neutralizing antibodies enhance the antitumor activities 
of rituximab and herceptin against lymphoma cells and lung Generation of Anti-CD59 scFv-Fc Construct
Jeong-Won Hong, et al.
34 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 1 February 2012
cancer  cells  (16,17).
    In  the  mid-1980s,  single-chain  Fv  (scFv)  constructs,  in 
which the isolated antibody variable heavy chain (VH) and 
variable light chain (VL) domains are joined by a flexible link-
er  of  15∼20  amino  acids,  were  developed.  The  small  size 
of scFv, its rapid clearance from the circulation, and its tu-
mor-penetrating properties make it a promising candidate for 
targeting  tumors  (16-22).  Recently,  the  scFv-Fc  strategy  has 
become  one  of  the  most  popular  methods  in  antibody  en-
gineering,  offering  numerous  advantages  over  traditional 
methods  (23).
    In the present study, using a previously established hybrid-
oma clone that produces a novel mAb (1E8) against human 
CD59, we cloned the 1E8 scVH and scVL genes, respectively. 
In  addition,  we  generated  a  1E8  scFv-Fc  recombinant  mAb 
a n d  e v a l u a t e d  i t s  C D C  e f f e c t s  i n  p r o s t a t i c  c a n c e r  c e l l  l i n e .
MATERIALS AND METHODS
Cells and reagents
The prostate cancer cell line PC3 was maintained in Dulbec-
co’s  modified  Eagle’s  medium  (DMEM)  that  was  supple-
mented with 10% fetal bovine serum (FBS). Rabbit comple-
ment (Cedarlane, Burlington, ON, Canada) was reconstituted 
in 1 ml of ice-cold distilled water, passed through a filter with 
po re  s iz e of  0 .2 2μm, and stored at −20
oC  until  use.  The 
E Z - C y t o x  C e l l  V i a b i l i t y  A s s a y  K i t  ( D a e i l  L a b ,  S e o u l ,  K o r e a )  
was  used.
Flow cytometry
The PC3 cells were seeded onto culture plates and allowed 
to adhere for 24 h. Cells (10
6) were incubated with saturating 
amounts  of  the  purified  mouse  1E8  or  a  control  im-
munoglobulin for 30 min at 4
oC. Thereafter, the cells were 
washed  twice  with  phosphate-buffered  saline  (PBS),  in-
cubated  with  fluorescein  isothiocyanate  (FITC)-conjugated 
goat anti-mouse secondary antibody for 20 min at 4
oC, and 
washed twice with PBS. The cells were fixed with 1% paraf-
ormaldehyde (Sigma-Aldrich, St. Louis, MO, USA). Cells were 
analyzed in a FACS apparatus (Beckman Coulter, Brea, CA, 
USA).
Cytotoxicity assay
PC3  cells  (5×10
3)  in  100μl  of  DMEM  supplemented  with 
10% FBS were seeded into a 96-well plate (SPL Lifesciences, 
Pocheon,  Korea).  The  plates  were  incubated  overnight  at 
37
oC in an atmosphere of 5% CO2, to allow the cells to adhere 
to the plate. The culture supernatant was removed, and the 
antibody (dissolved in serum-free DMEM at a concentration 
of 10μg/ml), either alone or in combination with 5% rabbit 
complement, was added to the cells. Cells in fresh medium 
without antibody or complement were used as the control. 
The  plates  were  incubated  for  3  h  at  37
oC .  A f t e r  t h e  i n -
cubation period, 10μl of the solution from the EZ-Cytox Cell 
Viability  Assay  kit  were  added  to  each  well  and  incubated 
at 37
oC in 5% CO2 for 4 h. The extent of the reduction to 
formazan  within  the  cells  was  quantified  by  measuring  the 
absorbance  at  450  nm  in  an  ELISA  reader.
RNA isolation and cDNA synthesis
The  hybridoma  cell  line  RV1E8,  which  produces  anti-CD59 
antibody, was cultured in RPMI medium that contained 10% 
heat-inactivated FBS (GIBCO). The culture was incubated un-
der at 37
oC in 5% CO2. After the cells had grown to a density 
of 10
6 cell, total RNA was purified using the Easy-BLUE RNA 
Extraction  kit  (iNtRON  Biotechnology,  Daejon,  Korea).
Construction of the scFv expression vector
The  genes  that  encode  the  variable  heavy  and  light  chains 
of the anti-CD59 antibody were derived using multiple over-
lap polymerase chain reaction (PCR). The sequences of the 
variable segments of the heavy and light chains were ampli-
fied using: the sense primers 5'-TCCTCCTCTGGTGGCGGTGG-
CTCGGGCGGTGGTGGGCAGGTGCAGCTGAAG-3'  (VH)  and 
5'-GGTTCCACTGGTGACGTGGCCCAGGCGGCCGACATCCAG
ATGACT-3' (VL); and the antisense primer: 5'-AGATTTGGGCT-
CAGCGGCCCCACCGGCCCCTGAGGAGACGGTGAC-3'  (VH) 
and  5'-ACCGCCACCAGAGGAGGAAGATCTAGAGGAACCAC-
CTCTGATTTCCAACTT-3'  (VL),  so  as  to  introduce  Sfi I  re-
striction enzyme sites (underlined). The amplified VH and VL 
genes were assembled into the scFv gene using a linker. We 
used the VL-F and VH-R primers that contained Sfi I sites in 
the PCR reaction (for a total of 40 cycles of 1 min at 94
oC, 
1 min at 60
oC, and 1.5 min at 72
oC), and purified the ampli-
cons using the QIAquick gel extraction kit (Qiagen, Hilden, 
Germany),  and  confirmed  by  DNA  sequencing  (Cosmo 
Genetech,  Seoul,  Korea).  The scFv DNA  products  were di-
gested  with  SfiI,  gel-purified,  and  then  ligated  into  the 
pOptiVEC-TOPO  expression  vector  (Dinona,  Seoul,  Korea), 
which  contains  the  human  CH2-CH3  fragment.Generation of Anti-CD59 scFv-Fc Construct
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Figure 1. Generation of the 1E8 scFv. (A) Amplification of the VH
and VL genes from hybridoma 1E8 cells. Lane M, 100-bp DNA ladder;
lane 1, VH PCR product; lane 2, VL PCR product; lane 3, 
VL-linker-VH PCR product. (B) Detection of the recombinant 
expression vector pOptiVEC-TOPO with 1E8 scFv-Fc. Lane M1, 1-kb 
DNA ladder; lane 4, construct digested with SfiI.
Figure 2. Nucleotide sequence and its deduced amino acid sequence
of the 1E8-scFv. The shadowed part represents the linker. 
Transient transfection assay
The day before transfection, 293T cells was cultured at 37
oC 
in  5%  CO2  to  a  density  of  about  5×10
5  cells/ml  in  6-well 
plates in DMEM medium that contained 10% heat-inactivated 
FBS. The cultures were 80% confluent on the day of trans-
fection. The scFv vector was transfected into 293T cells using 
the Effectene transfection reagent (Qiagen). After incubation 
for 3 days, the culture supernatant was tested by flow cyto-
metry.
Purification of anti-CD59 antibody
Th e  su pe rn at an t of  th e  t ran si en t ly  tr an sfe c te d  c el ls w as  ap-
plied  to  a  recombinant  protein  column  (GE  Healthcare, 
Uppsala, Sweden) that had been previously equilibrated with 
binding buffer (20 mM sodium phosphate [pH 7.2], 0.15 M 
NaCl). The column was washed with binding buffer, and pro-
tein was eluted with elution buffer (0.1 M glycine-HCl [pH 
3.0]). The eluted fractions were collected in tubes that con-
tained neutralizing buffer (1 M Tris-HCl, [pH 8.0]), so as to 
adjust the pH to approximately 7. Finally, the purified sam-
ples were dialyzed against PBS. The purity of the eluted anti-
body fraction was analyzed by SDS-PAGE on 10% gels under 
reducing or non-reducing conditions. Protein bands were vi-
sualized  by  Coomassie  blue  staining.  After  electrophoresis, 
the  proteins  in  the  gel  were  transferred  to  a  nitrocellulose 
m e m b r a n e  ( W h a t m a n ,  D a s s e l ,  G e r m a n y ) ,  w h i c h  w a s  t h e n  
blocked with 5% skim milk in PBS. The membrane was in-
cubated with a 1：5,000 dilution of HRP-conjugated goat an-
ti-human IgG (Jackson ImmunoResearch Laboratories, Baltim-
ore, MD, USA) for 1 h at room temperature, and then washed 
four times with PBST (PBS with 0.05% tween 20). Thereafter, 
the immunoreactive bands were visualized using an enhanced 
chemiluminescence detection system (ECL; Amersham Phar-
macia  Biotech,  Uppsala,  Sweden).
RESULTS
Generation of 1E8 scFv
The VH and VL DNA fragments of mouse 1E8 were success-
fully  amplified  with  the  VH-F/R  and  VL-F/R  primers,  res-
pectively. The size of the amplified VH DNA was 351 bp and 
that of the amplified VL DNA was 327 bp. Using VL and VH 
DNA, a 781bp DNA were overlapped by linking peptide in-
serted in the middle of VL and VH (Fig. 1A). The purified 
1 E 8 - s c F v  g e n e  f r a g m e n t  w a s  d i g e s t e d  w i t h  Sfi I  and  cloned Generation of Anti-CD59 scFv-Fc Construct
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Figure 3. Immunoreactivity of the 
anti-CD59 scFv-Fc for CCRF-CEM 
cells. The flow cytometry histogram 
demonstrates that 1E8 scFv-Fc binds
to CCRF-CEM cells. (A) Negative 
control (FITC-labeled human IgG); 
(B) positive control (FITC-labeled 
mouse 1E8); (C) 1E8-scFv (FITC- 
labeled goat anti-human IgG).
Figure 4. Identification of purified recombinant 1E8 scFv-Fc on 
SDS-PAGE. Anti-CD59 scFv-Fc was purified using an immobilized 
protein A column and detected by Western blotting (A) and 
Coomassie blue staining (B). M, marker; LS, supernatant of the 
transfectant; FT, after Mabselect Sure purification; #1-3, washing 
buffer; #4-7, elution fraction; R, reducing conditions; NR, 
non-reducing conditions. Note clear bands of 120 kDa at elusion 
fraction (#5-7) and of 120 kDa at non-reducing and 55 kDa at 
reducing condition.
into the pOptiVEC-TOPO transfer vector. The ligation product 
was  transformed  into  competent  cells  and  positive  colonies 
were selected after incubation at 37
oC. Plasmid DNA was ex-
tracted using a Mini-Prep kit (Qiagen). A positive clone was 
identified by restriction enzyme digestion (Fig. 1B). The se-
quencing results showed that 1E8-scFv contained the linking 
peptide  (Fig.  2).
Expression of soluble 1E8 scFv-Fc
The constructs derived from subcloning into the pOptiVEC- 
T O P O  v e c t o r  w e r e  t r a n s f e c t e d  i n t o  2 9 3 T  c e l l s  u s i n g  t h e  
Effectene transfection reagent. The supernatant of the trans-
fected culture was tested for reactivity with CCRF-CEM cells 
by flow cytometry. The positive binding rates of the mouse 
1E8  and  1E8  scFv-Fc  were  97.8%  and  98.8%,  respectively 
(Fig.  3).
Purification of the 1E8 scFv-Fc construct
The recombinant antibody contained the human Fc fragment. 
Antibody  from  the  supernatant  was  successfully  purified  in 
one  step  by  affinity  chromatography  using  an  immobilized 
protein A column. The purified 1E8 scFv-Fc was analyzed by 
SDS-PAGE  and  Western  blotting.  SDS-PAGE  disclosed  dis-
create  bands  of  120  kDa  at  elution  fraction  (Fig.  4A). 
SDS-PAGE under reducing conditions revealed a single band 
of ∼55 kDa. The molecular mass of the dimeric scFv-Fc un-
der  non-reducing  conditions  was  ∼120  kDa  (Fig.  4B).
Comparisons of CDC effect between the mouse 1E8 
and 1E8 scFv-Fc in prostate cancer cell line
To examine the expression of CD59 antigens by prostate can-
c e r  c e l l s ,  w e  a s s e s s e d  t h e  b i n d i n g  o f  m o u s e  1 E 8  a n d  1 E 8  
scFv-Fc on PC3 cells by FACS analysis. The mouse 1E8 and 
1E8 scFv-Fc well recognized cell surface CD59 on PC3 cells 
(Fig. 5A). To compare the neutralizing activity of mouse 1E8 
and 1E8 scFv-Fc, we tested the susceptibility of PC3 to com-
plement-mediated damage. Approximately 20% and 25%, re-
spectively, of the PC3 cells were sensitized by mouse 1E8 and 
1E8  scFv-Fc  to  killing  by  complement  (Fig.  5B).
DISCUSSION
In the present study, using a previously established hybrid-
oma clone that produces a novel mAb (1E8) directed against 
human CD59, we cloned the 1E8 scVH and scVL genes. We 
generated a 1E8 scFv-Fc recombinant antibody and obtained 
the nucleotide sequence of the construct. In addition, we re-
vealed that this recombinant 1E8 scFv-Fc mAb enhance CDC 
effect  in  CD59  expressing  prostate  cancer  cell  line.
    The well known advantage of single chain minibody con-
taining only CH2 and CH3 domain is that the scFv-Fc mini-
body easily penetrates solid tumors as it is smaller than the 
intact full chimeric antibody. Recently, it has been reported 
that anti-CD20 scFv-Fc (TRU-015) is more effective than ritux-
imab in vivo against lymphoma. A clinical trial of TRU-015 Generation of Anti-CD59 scFv-Fc Construct
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Figure 5. Effects of 1E8 scFv-Fc on 
complement-dependent cytotoxicity 
for CD59-expressing PC3 cells. (A) 
CD59 is highly expressed on PC3 
cells. (B) 1E8 scFv-Fc enhances com-
plement-dependent cytotoxicity in 
the presence of rabbit complement 
(RC) showing similar effect with 
mouse 1E8. negative control (IgG); 
mouse 1E8 (1E8). The numbers of 
viable cells were evaluated in a 
cytotoxicity assay.
for the treatment of lymphoma and inflammatory disease is 
in  progress  (23).  However,  scFv-Fc  minibody  themselves 
have  limited  usage  as  tumor-targeting  agents  in  vivo,  gen-
erally  demonstrateing  very  rapid  clearance  from  the  circu-
lation in animal models and revealing unstable characteristics 
during large scale production. (24,25). For the scFv-Fc mini-
body to be used as a therapeutic antibody, the antibody pro-
duction problem would have to be resolved and its effective-
ness  would  have  to  be  proven  in  animal  experiments.
    We describe a method for engineering mouse 1E8 through 
genetic fusion of 1E8 scFv to the human CH2-CH3 domains. 
We  obtained  and  presented  the  nucleotide  sequence  of 
1 E 8 - s c F v  ( F i g .  2 ) .  C u r r e n t l y ,  t h i s  D N A  s e q u e n c e  o f  m A b  
a g a i n s t  C D 5 9  c a n  n o t  b e  e a s i l y  a v a i l a b l e  i n  t h e  p u b l i c  
domain.  We  found  that  the  level  of  immunoreactivity  of 
scFv-Fc was similar to that of the mouse 1E8 mAb (Fig. 3). 
This  implies  that  the  constructed  1E8  scFv-Fc  is  structurally 
stable and bind effectively. The recombinant 1E8 scFv-Fc was 
isolated  from  the  culture  supernatants  by  protein  A  affinity 
chromatography and analyzed. The results of the SDS-PAGE 
and Western blot analyses showed discrete bands of expected 
molecular  size,  so  the  product  was  a  monomer  under  re-
ducing  conditions  but  formed  a  homodimer  under  non-re-
ducing conditions (Fig. 4). The large molecular mass of the Generation of Anti-CD59 scFv-Fc Construct
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product in the non-reducing condition is presumed to reflect 
glycosylation. These results suggest that 1E8 scFv-Fc is a di-
meric antibody, similar to the intact antibody. This could be 
an important factor for the structural stability of 1E8 scFv-Fc. 
    The complement cascade is an effector system that is called 
into  action  by  a  therapeutic  mAb.  However,  the  over-ex-
pression  of  complement  regulatory  proteins  by  tumor  cells 
blocks the destructive effects of complement. Recently, it was 
shown that the combined use of anti-CD59 antibodies and rit-
uximab  diminished  the  resistance  of  B  lymphoma  cells  to 
complement-mediated  killing,  and  the  combination  of  an-
ti-CD59 antibodies and herceptin was found to be effective 
for enhancing the complement-mediated killing of lung can-
cer cells (16,17). Interestingly, it has been reported that CD59 
is over-expressed by prostate cancer cells and is linked to the 
p r o g r e s s  a n d  t h e  p r o g n o s i s  o f  p r o s t a t e  c a n c e r  ( 1 4 ) .  I n  t h e  
present study, we demonstrated the enhancement of CDC by 
an  anti-CD59  monoclonal  antibody  (mouse  1E8).  Over-ex-
pression of CD59 was demonstrated (Fig. 5A) in the prostate 
cancer cell line PC3, and CDC was shown to be induced by 
the combination of rabbit complement with mouse 1E8 and 
1E8  scFv-Fc  (Fig.  5B).  This  implies  that  recombinant  1E8 
scFv-Fc antibody effectively control the CDC-inhibitory func-
tions of CD59 by binding functionally active domain of CD59.
    In the present study, the usefulness of 1E8 scFv-Fc mini-
body in combating prostate cancer was evaluated as a possi-
ble  adjvant  cancer  therapeutic  agent.  The  recombinant  1E8 
antibody therapy in combination with anti-cancer drugs is un-
der  investigation  in  our  laboratoy.
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